Bortezomib induction of C/EBPβ mediates Epstein-Barr virus lytic activation in Burkitt lymphoma

Blood

Volumn 117, Issue 23, 2011, Pages 6297-6303

  Shirley, Courtney M ^a   Chen, Jianmeng ^a   Shamay, Meir ^a   Li, Huili ^a   Zahnow, Cynthia A ^a   Hayward, S Diane ^a   Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; BORTEZOMIB; CCAAT ENHANCER BINDING PROTEIN BETA; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; PROTEASOME; PROTEIN CHOP10; THAPSIGARGIN; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

ARTICLE; BURKITT LYMPHOMA; CANCER CELL; CONTROLLED STUDY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; EPSTEIN BARR VIRUS; GENE EXPRESSION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN FUNCTION; UNFOLDED PROTEIN RESPONSE; VIRUS ACTIVATION;

EID: 79959405603     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-332379     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. (Pubitemid 40372904)
2. Parkin DM. The global health burden of infectionassociated cancers in the year 2002. Int J Cancer. 2006;118(12):3030-3044.
3. Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008. Ann Oncol. 2009; 20(9):1472-1482.
4. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350(13):1328-1337. (Pubitemid 38375368)
5. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol. 2008;6(12):913-924.
6. Cohen JI, Bollard CM, Khanna R, Pittaluga S. Current understanding of the role of Epstein-Barr virus in lymphomagenesis and therapeutic approaches to EBV-associated lymphomas. Leuk Lymphoma. 2008;49(suppl 1):27-34.
7. Farrell PJ. Tumour viruses-could they be an Achilles' heel of cancer? Eur J Cancer. 2002; 38(14):1815-1816. (Pubitemid 35247466)
8. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr viruspositive B-cell lymphomas. J Virol. 2004;78(4): 1893-1902. (Pubitemid 38176721)
9. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571-2578. (Pubitemid 46425904)
10. Fu DX, Tanhehco Y, Chen J, et al. Bortezomibinduced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med. 2008; 14(10):1118-1122.
11. Klass CM, Krug LT, Pozharskaya VP, Offermann MK. The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood. 2005;105(10):4028-4034. (Pubitemid 40656152)
12. Feng WH, Cohen JI, Fischer S, et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004;96(22): 1691-1702. (Pubitemid 39585638)
13. Fu DX, Tanhehco YC, Chen J, et al. Virusassociated tumor imaging by induction of viral gene expression. Clin Cancer Res. 2007;13(5): 1453-1458. (Pubitemid 46450435)
14. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006; 107(12):4907-4916. (Pubitemid 43882644)
15. Strasser A, Puthalakath H. Fold up or perish: unfolded protein response and chemotherapy. Cell Death Differ. 2008;15(2):223-225.
16. Dong H, Chen L, Chen X, et al. Dysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cells. Leuk Lymphoma. 2009;50(6):974-984.
17. Countryman J, Jenson H, Seibl R,Wolf H, Miller G. Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol. 1987;61(12):3672-3679. (Pubitemid 18011461)
18. Lieberman PM, Hardwick JM, Sample J, Hayward GS, Hayward SD. The zta transactivator involved in induction of lytic cycle gene expression in Epstein-Barr virus-infected lymphocytes binds to both AP-1 and ZRE sites in target promoter and enhancer regions. J Virol. 1990;64(3): 1143-1155. (Pubitemid 20087752)
19. Lin Z, Yin Q, Flemington E. Identification of a negative regulatory element in the Epstein-Barr virus Zta transactivation domain that is regulated by the cell cycle control factors c-Myc and E2F1. J Virol. 2004;78(21):11962- 11971. (Pubitemid 39390781)
20. Miller G, El-Guindy A, Countryman J, Ye J, Gradoville L. Lytic cycle switches of oncogenic human gammaherpesviruses. Adv Cancer Res. 2007;97:81-109. (Pubitemid 46528986)
21. Rennekamp AJ, Wang P, Lieberman PM. Evidence for DNA hairpin recognition by Zta at the Epstein-Barr virus origin of lytic replication. J Virol. 2010;84(14):7073-7082.
22. Hattori T, Ohoka N, Inoue Y, Hayashi H, Onozaki K. C/EBP family transcription factors are degraded by the proteasome but stabilized by forming dimer. Oncogene. 2003;22(9):1273-1280. (Pubitemid 36384589)
23. WeiW, Yang H, Menconi M, Cao P, Chamberlain CE, Hasselgren PO. Treatment of cultured myotubes with the proteasome inhibitor beta-lactone increases the expression of the transcription factor C/EBPbeta. Am J Physiol Cell Physiol. 2007; 292(1):C216-226. (Pubitemid 46115132)
24. Wu FY, Chen H, Wang SE, et al. CCAAT/enhancer binding protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle. J Virol. 2003;77(2): 1481-1500. (Pubitemid 36055569)
25. Huang J, Chen H, Hutt-Fletcher L, Ambinder RF, Hayward SD. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol. 2003;77(24):13267-13274. (Pubitemid 37494322)
26. Wu FY, Wang SE, Chen H, Wang L, Hayward SD, Hayward GS. CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle. J Virol. 2004;78(9):4847-4865. (Pubitemid 38501105)
27. Huang J, Liao G, Chen H, et al. Contribution of C/EBP proteins to Epstein-Barr virus lytic gene expression and replication in epithelial cells. J Virol. 2006;80(3):1098-1109. (Pubitemid 43134067)
28. Pal R, Janz M, Galson DL, et al. C/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood. 2009;114(18):3890-3898.
29. Meir O, Dvash E, Werman A, Rubinstein M. C/EBP-beta regulates endoplasmic reticulum stress-triggered cell death in mouse and human models. PLoS ONE. 2010;5(3):e9516.
30. Takada K. Role of Epstein-Barr virus in Burkitt's lymphoma. Curr Top Microbiol Immunol. 2001; 258:141-151. (Pubitemid 32574038)
31. Ji Jung E, Mie Lee Y, Lan Lee B, Soo Chang M, Ho Kim W. Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell line. Anticancer Drugs. 2007; 18(1):79-85. (Pubitemid 44949797)
32. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell. 1991;67(3):569-579. (Pubitemid 121001471)
33. Li Y, Bevilacqua E, Chiribau CB, et al. Differential control of the CCAAT/enhancer-binding protein beta (C/EBPbeta) products liver-enriched transcriptional activating protein (LAP) and liverenriched transcriptional inhibitory protein (LIP) and the regulation of gene expression during the response to endoplasmic reticulum stress. J Biol Chem. 2008;283(33):22443-22456.
34. Nawrocki ST, Carew JS, Dunner K Jr, et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 2005;65(24):11510-11519. (Pubitemid 41821709)
35. Armstrong JL, Flockhart R, Veal GJ, Lovat PE, Redfern CP. Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells. J Biol Chem. 2010;285(9): 6091-6100.
36. Zou P, Kawada J, Pesnicak L, Cohen JI. Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J Virol. 2007;81(18):10029-10036. (Pubitemid 350067706)
37. Garrido JL, Maruo S, Takada K, Rosendorff A. EBNA3C interacts with Gadd34 and counteracts the unfolded protein response. Virol J. 2009;6: 231.
38. Cheng G, Feng Z, He B. Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2alpha dephosphorylation by the gamma(1)34.5 protein. J Virol. 2005;79(3):1379-1388. (Pubitemid 40459085)
39. Buchkovich NJ, Yu Y, Pierciey FJ Jr, Alwine JC. Human cytomegalovirus induces the endoplasmic reticulum chaperone BiP through increased transcription and activation of translation by using the BiP internal ribosome entry site. J Virol. 2010; 84(21):11479-11486.
40. Lee DY, Sugden B. The LMP1 oncogene of EBV activates PERK and the unfolded protein response to drive its own synthesis. Blood. 2008; 111(4):2280-2289. (Pubitemid 351451435)
41. Hsiao JR, Chang KC, Chen CW, et al. Endoplasmic reticulum stress triggers XBP-1-mediated up-regulation of an EBV oncoprotein in nasopharyngeal carcinoma. Cancer Res. 2009;69(10): 4461-4467.
42. Sun CC, Thorley-Lawson DA. Plasma cellspecific transcription factor XBP-1s binds to and transactivates the Epstein-Barr virus BZLF1 promoter. J Virol. 2007;81(24):13566-13577. (Pubitemid 350247850)
43. Bhende PM, Dickerson SJ, Sun X, Feng WH, Kenney SC. X-box-binding protein 1 activates lytic Epstein-Barr virus gene expression in combination with protein kinase D. J Virol. 2007;81(14): 7363-7370. (Pubitemid 47047825)
44. McDonald C, Karstegl CE, Kellam P, Farrell PJ. Regulation of the Epstein-Barr virus Zp promoter in B lymphocytes during reactivation from latency. J Gen Virol. 2010;91(pt 3):622-629.
45. Bristol JA, Robinson AR, Barlow EA, Kenney SC. The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins. J Virol. 2010;84(23):12362-12374.